Abstract
BackgroundNilotinib is a BCR-ABL inhibitor designed to be more potent and selective than imatinib. Imatinib was the first of a new class of drugs that act by specifically inhibiting a...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Hospital Pharmacy: Science and Practice
Paper Title
Journal
Date
